4.7 Article

Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling

Journal

JOURNAL OF NATURAL PRODUCTS
Volume 85, Issue 4, Pages 765-775

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jnatprod.1c00761

Keywords

-

Funding

  1. National Natural Science Foundation of China [82173856]
  2. Natural Science Foundation of Zhejiang Province [LY21H300005, LBY20H300001]
  3. Wenzhou Municipal Science and Technology Bureau [ZY2020025, H20210009]

Ask authors/readers for more resources

Telocinobufagin can inhibit proliferation and metastasis, and induce apoptosis in non-small-cell lung cancer cells. Its mechanism of action involves inhibition of STAT3 phosphorylation and downstream targets, as well as interference with IL-6-induced STAT3 nuclear translocation.
Non-small-cell lung carcer (NSCLC), the main histological subtype of lung cancer, is responsible for significant morbidity and mortality worldwide. Telocinobufagin, an active compound of the Chinese traditional medicine ChanSu, has antitumor effects, but its mechanism of action remains unknown. Therefore, we investigated the effect of telocinobufagin on NSCLC growth and metastasis and its possible mechanism of action, in vitro and in vivo. Cell proliferation, migration, and apoptosis were measured by methyl thiazol tetrazolium assay, colony formation, 5-ethynyl-2'-deoxyuridine incorporation, Transwell migration, wound healing, and flow cytometry analysis. A mouse xenograft model was used to evaluate tumor formation in vivo. Telocinobufagin was found to suppress proliferation and metastasis and induce apoptosis in human NSCLC cells. Moreover, telocinobufagin was able to significantly inhibit STAT3 phosphorylation at tyrosine 705 (Y-705) and its downstream targets. Additionally, telocinobufagin also impaired the IL-6-induced nuclear translocation of STAT3. Consistent with the in vitro experiments, telocinobufagin reduced the A549 xenograft tumor burden and the levels of P-STAT3(Y705), MCL1, BCL2, and cleaved PARP1 in vivo. These results support telocinobufagin as a promising STAT3 signaling inhibitor candidate for the treatment of NSCLC patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available